Reactivation of hepatitis B virus with rituximab
- 10 May 2005
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Drug Safety
- Vol. 4 (3), 599-608
- https://doi.org/10.1517/14740338.4.3.599
Abstract
Rituximab has become a useful drug for the treatment of non-Hodgkin’s lymphoma (NHL) and such autoimmune diseases as idiopathic thrombocytopenic purpura and rheumatoid arthritis. When combined with cytotoxic agents, rituximab showed synergistic effects for the treatment of NHL. In such treatment, hepatitis B virus (HBV) reactivation is a crucial complication when patients are treated with immunosuppressive or chemotherapeutic agents. Despite its treatment efficacy, several studies have pointed out unusual viral infections after its administration that resulted in fatal hepatitis due to HBV reactivation. In the cases at the authors’ institute, the authors analysed the kinetics of HBV antibodies, HBV-reactivation timing, and the prophylactic efficacy of lamivudine. The authors reviewed their cases and the previous literature to clarify the characteristics of HBV-reactivated patients who were administered rituximab.Keywords
This publication has 50 references indexed in Scilit:
- Prolonged Clinical and Molecular Remission in Patients With Low-Grade or Follicular Non-Hodgkin's Lymphoma Treated With Rituximab Plus CHOP Chemotherapy: 9-Year Follow-UpJournal of Clinical Oncology, 2004
- Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxisGut, 2004
- New Treatment Approaches To Indolent Non-Hodgkin’s LymphomaSeminars in Oncology, 2004
- Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapyBlood, 2003
- Efficacy of Lamivudine in Patients with Hematologic Malignancies Receiving Chemotherapy and Precore Mutant Chronic Active Hepatitis BActa Haematologica, 2002
- Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximabAmerican Journal of Hematology, 2001
- Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivationBritish Journal of Haematology, 2000
- Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigenHepatology, 2000
- Interferon and cyclosporin A in the treatment of fulminant viral hepatitisThe Esophagus, 1995
- Fulminant hepatic failure in non-Hodgkin lymphoma patients treated with chemotherapyEuropean Journal of Cancer, 1992